Johnson & Johnson colorectal cancer trial data reveal promising long-term efficacy of amivantamab-vmjw plus chemotherapy

Johnson & Johnson (NYSE: JNJ) has announced extended follow-up results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The updated data, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, demonstrated durable responses across both first- and second-line treatment settings, reinforcing the company’s pursuit of Phase 3 validation and potentially establishing a new paradigm in colorectal cancer therapy.

How does amivantamab’s dual-targeting approach change expectations for EGFR/MET-driven metastatic colorectal cancer?

The OrigAMI-1 trial enrolled patients with metastatic colorectal cancer who were confirmed to be wild-type for KRAS, NRAS, and BRAF mutations and did not have HER2 amplification. These patients were treated with intravenous amivantamab combined with either FOLFOX or FOLFIRI chemotherapy. The median follow-up of 16 months provided one of the longest windows into amivantamab’s activity in this population, and the results show meaningful clinical impact, particularly among first-line patients.

In the overall cohort of 43 patients, the confirmed overall response rate reached 51 percent, with a median time to response of just over eight weeks. Response durability clocked in at a median of 9.3 months. In the first-line subgroup, the response rate surged to 73 percent, with median duration of response not yet reached by the time of data cutoff. Four patients in this group were able to proceed to curative-intent surgery, an uncommon outcome in metastatic colorectal cancer. In the second-line setting, response rates were 44 percent with a median duration of response of 7.4 months, and over a third of these patients remained on therapy for more than one year. Three patients continued beyond two years.

Importantly, the trial also enrolled 30 patients with liver metastases, a subgroup often associated with worse prognosis. In this subset, the confirmed response rate was 57 percent, and median progression-free survival reached 11.3 months. These outcomes suggest that dual EGFR and MET inhibition may have a clinically meaningful impact in this challenging metastatic population, particularly where MET-driven resistance has historically undermined EGFR-based therapies.

Why are these results strategically important for Johnson & Johnson’s broader oncology ambitions?

The results from the OrigAMI-1 study reinforce the strategic rationale behind Johnson & Johnson’s long-term investment in amivantamab as a modular bispecific platform. Already approved in multiple indications for non-small cell lung cancer, amivantamab’s performance in colorectal cancer could meaningfully expand its addressable market and strengthen the company’s position in solid tumor oncology.

Colorectal cancer remains one of the most prevalent and deadly cancers globally. Traditional treatment for RAS/BRAF wild-type metastatic disease often involves EGFR inhibitors combined with chemotherapy, but resistance mechanisms—particularly involving MET signaling—frequently emerge, limiting durability. Johnson & Johnson’s dual-targeting approach directly confronts this resistance pathway, potentially extending the window of therapeutic benefit.

Should amivantamab demonstrate similar efficacy and tolerability in ongoing pivotal trials, Johnson & Johnson may not only secure a new colorectal cancer indication but also establish a competitive edge against rival EGFR-focused antibodies and emerging biologics. The company is also testing a subcutaneous formulation of amivantamab in ongoing Phase 3 trials, OrigAMI-2 and OrigAMI-3, which could further differentiate its platform by improving ease of administration and patient adherence.

What execution and clinical development risks could limit the pathway to regulatory success?

While the durability and response data are compelling, they stem from a modestly sized, early-phase, open-label trial. As with all exploratory studies, confirmation in larger randomized cohorts is critical. Amivantamab’s current approval is centered on EGFR exon 20 insertion mutations and NSCLC settings. Applying it successfully to colorectal cancer requires a shift in oncologists’ expectations and careful navigation of the competitive, guideline-driven reimbursement landscape.

Operational risk exists in scaling the therapy to broader populations without compromising tolerability. While adverse events in OrigAMI-1 were manageable—most commonly neutropenia—nine percent of patients still discontinued treatment due to side effects. Furthermore, the therapeutic window in colorectal cancer is more crowded and cost-sensitive than in rare lung cancer subtypes, meaning that any toxicity tradeoff will face tougher scrutiny from payers and clinicians.

Another critical element is the ongoing validation of biomarker strategies. The OrigAMI-1 trial relied on rigorous genotyping to exclude patients with KRAS, NRAS, BRAF, and HER2 alterations. Ensuring that such biomarker testing is readily available and economically viable in real-world settings will be central to commercial success.

How could this development reshape the competitive landscape in colorectal cancer therapy?

Johnson & Johnson’s bispecific targeting strategy directly challenges the standard single-pathway approach employed by current anti-EGFR therapies like cetuximab and panitumumab. If the dual-targeting mechanism proves more effective across lines of therapy and subgroups like liver metastases, it could displace long-standing regimens and force a reevaluation of combination strategies that currently dominate clinical practice.

Companies developing MET inhibitors or bispecific agents targeting other receptor tyrosine kinases will closely watch these results. If amivantamab sets a new efficacy baseline in wild-type mCRC, it could lead to increased interest in multi-pathway targeting and potentially crowd out single-agent MET or EGFR therapies not designed for dual inhibition.

Also in play is the question of subcutaneous delivery. Johnson & Johnson is now advancing trials with a subcutaneous formulation of amivantamab, which, if effective, would represent a significant advantage in terms of infusion burden, patient experience, and healthcare system throughput. This route could also make amivantamab-based regimens more feasible in community oncology settings, where intravenous biologics pose logistical hurdles.

What should institutional investors and industry stakeholders monitor moving forward?

The biggest catalyst for Johnson & Johnson’s colorectal cancer ambitions will be the data readouts from OrigAMI-2 and OrigAMI-3, both randomized Phase 3 studies that aim to validate amivantamab’s efficacy in first- and second-line settings. These trials will define whether amivantamab’s early promise translates into a regulatory-grade treatment option. If successful, the drug could be positioned for submission in late 2027 or 2028.

Investors will also be watching closely for any signals of label expansion activity beyond colorectal cancer, especially given the broader basket trials evaluating amivantamab in other EGFR/MET-driven tumors. These parallel programs could provide synergistic momentum across Johnson & Johnson’s oncology franchise, particularly as more oncologists seek options that delay resistance without compromising safety.

While no immediate market reaction is likely based on interim Phase 1b/2 data, the durable responses observed here could strengthen analyst expectations for the long-term revenue potential of the amivantamab franchise, particularly if expanded indications build on the current NSCLC footprint.

Key takeaways on what Johnson & Johnson’s amivantamab colorectal cancer data signal for strategy, competition, and next steps

• Johnson & Johnson’s updated Phase 1b/2 OrigAMI-1 data strengthen the clinical case for amivantamab-vmjw as a differentiated EGFR and MET dual-targeting therapy in RAS/BRAF wild-type metastatic colorectal cancer, a segment with limited durable options.

• The high response rates and extended durability, particularly in first-line patients and those with liver metastases, suggest that dual pathway inhibition may meaningfully delay resistance compared with historical EGFR-based regimens.

• These results materially de-risk the ongoing Phase 3 OrigAMI-2 and OrigAMI-3 programs, shifting the investment and regulatory narrative from proof of concept toward execution and scalability.

• If Phase 3 outcomes confirm these early signals, amivantamab could disrupt entrenched colorectal cancer treatment algorithms and pressure existing EGFR monoclonal antibodies that do not address MET-driven resistance.

• The ability of some patients to proceed to curative-intent surgery highlights a potential downstream impact on treatment sequencing, surgical decision-making, and long-term outcomes in metastatic disease.

• Safety and discontinuation rates appear manageable, but broader Phase 3 populations will test whether tolerability remains acceptable in real-world, cost-sensitive colorectal cancer settings.

• For Johnson & Johnson, success in colorectal cancer would significantly expand the commercial and strategic footprint of the amivantamab franchise beyond lung cancer, reinforcing its bispecific antibody platform as a core oncology growth driver.

• The next inflection point for investors and competitors will be randomized Phase 3 efficacy and survival data, which will ultimately determine whether amivantamab can secure regulatory approval and guideline adoption in colorectal cancer.